Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for iBio, Inc. (IBIO : AMEX)
 
 • Company Description   
Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.

Number of Employees: 75

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.28 Daily Weekly Monthly
20 Day Moving Average: 2,050,591 shares
Shares Outstanding: 218.17 (millions)
Market Capitalization: $61.09 (millions)
Beta: -4.65
52 Week High: $1.76
52 Week Low: $0.22
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.11% 0.11%
12 Week -14.45% -5.96%
Year To Date -49.00% -48.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
8800 HSC Parkway
-
Bryan,TX 77807
USA
ph: 979-446-0027
fax: 302-356-1173
ir@ibioinc.com http://www.ibioinc.com
 
 • General Corporate Information   
Officers
Thomas F. Isett - Chairman and Chief Executive Officer
Robert Lutz - Chief Financial Officer
Linda Armstrong - Director
Alexandra Kropotova - Director
William Clark - Director

Peer Information
iBio, Inc. (CORR.)
iBio, Inc. (RSPI)
iBio, Inc. (CGXP)
iBio, Inc. (BGEN)
iBio, Inc. (GTBP)
iBio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 451033203
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/26/22
Share - Related Items
Shares Outstanding: 218.17
Most Recent Split Date: 6.00 (0.10:1)
Beta: -4.65
Market Capitalization: $61.09 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/26/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.77
Price/Cash Flow: -
Price / Sales: 21.72
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: -20.00%
Sales Growth
vs. Year Ago Period: 153.99%
vs. Previous Quarter: 1,056.55%
ROE
03/31/22 - -45.72
12/31/21 - -38.17
09/30/21 - -33.06
ROA
03/31/22 - -32.55
12/31/21 - -27.58
09/30/21 - -24.06
Current Ratio
03/31/22 - 7.28
12/31/21 - 8.09
09/30/21 - 11.09
Quick Ratio
03/31/22 - -
12/31/21 - 7.85
09/30/21 - 11.02
Operating Margin
03/31/22 - -1,540.45
12/31/21 - -2,361.10
09/30/21 - -1,602.81
Net Margin
03/31/22 - -1,177.85
12/31/21 - -1,737.25
09/30/21 - -1,133.19
Pre-Tax Margin
03/31/22 - -1,177.96
12/31/21 - -1,737.49
09/30/21 - -1,133.47
Book Value
03/31/22 - 0.36
12/31/21 - 0.42
09/30/21 - 0.46
Inventory Turnover
03/31/22 - 0.58
12/31/21 - 1.71
09/30/21 - 2.64
Debt-to-Equity
03/31/22 - 0.28
12/31/21 - 0.24
09/30/21 - 0.31
Debt-to-Capital
03/31/22 - 21.83
12/31/21 - 19.61
09/30/21 - 23.95
 

Powered by Zacks Investment Research ©